Company intelligence / Profile preview

Constellation Pharmaceuticals

Cambridge, Massachusetts, United States of Americaconstellationpharma.com ↗

Ownership: Public · CNST
Development stage: Other

Overview

Constellation developed pelabresib (CPI-0610), a BET inhibitor for myelofibrosis. In the Phase 3 MANIFEST-2 study, the combination of pelabresib and ruxolitinib showed improvement in all hallmarks of myelofibrosis versus placebo plus ruxolitinib. The company also developed CPI-0209, an EZH2 inhibitor for advanced malignancies, which showed comprehensive target engagement in Phase 1 data[1][6][10].

Therapeutic areas: HematologyOncology
Modalities: Small molecules
Industry: Biotech

Partnerships

Leukemia and Lymphoma Society (LLS)

Beyond the preview

Go deeper on Constellation Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Constellation Pharmaceuticals.